IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.293
EU - Europa 2.277
AS - Asia 901
AF - Africa 40
SA - Sud America 4
OC - Oceania 3
Totale 5.518
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.273
CN - Cina 607
IT - Italia 591
IE - Irlanda 441
SE - Svezia 381
FI - Finlandia 373
DE - Germania 167
SG - Singapore 152
UA - Ucraina 124
TR - Turchia 65
BE - Belgio 42
IN - India 42
CI - Costa d'Avorio 39
AT - Austria 37
GB - Regno Unito 33
FR - Francia 29
CA - Canada 20
CZ - Repubblica Ceca 16
NL - Olanda 13
HK - Hong Kong 12
VN - Vietnam 8
IR - Iran 7
PL - Polonia 6
ES - Italia 4
HU - Ungheria 4
JP - Giappone 4
AR - Argentina 3
CH - Svizzera 3
LU - Lussemburgo 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
RO - Romania 3
PK - Pakistan 2
RU - Federazione Russa 2
EG - Egitto 1
HR - Croazia 1
KR - Corea 1
PE - Perù 1
SI - Slovenia 1
TW - Taiwan 1
Totale 5.518
Salva come PNG Salva come JPEG
Città #
Dublin 441
Chandler 408
Ann Arbor 338
Parma 189
Dearborn 155
Jacksonville 144
Boardman 122
Ashburn 106
Singapore 104
Beijing 100
Shanghai 98
Nanjing 84
Princeton 67
Izmir 65
New York 64
Bremen 61
Milan 45
Nanchang 40
San Mateo 40
Abidjan 39
Shenyang 37
Vienna 36
Wilmington 34
Helsinki 32
Chicago 29
Kunming 28
Los Angeles 28
Hebei 27
Hefei 25
Brussels 24
Jinan 23
Modena 23
Des Moines 22
Redmond 20
Seattle 18
Tianjin 17
Woodbridge 17
Pune 15
Norwalk 14
Santa Clara 14
Jiaxing 12
Neviano degli Arduini 12
Wayne 12
Leawood 11
Changsha 10
Dallas 10
Fremont 10
Hong Kong 10
Toronto 10
Amsterdam 9
Guangzhou 9
Bologna 8
Dong Ket 8
Fuzhou 8
Grafing 8
Munich 8
Ardabil 7
Augusta 7
Binche 7
Leuven 7
Reggio Emilia 7
Rome 7
Brno 6
Chengdu 6
Follonica 6
Monmouth Junction 6
Montreal 6
Redwood City 6
Salsomaggiore Terme 6
Zhengzhou 6
Fairfield 5
London 5
Ningbo 5
Casalgrande 4
Florence 4
Gainesville 4
Genoa 4
Haikou 4
Houston 4
Mons 4
Piacenza 4
Soliera 4
Taiyuan 4
Verona 4
Albano Laziale 3
Aveiro 3
Bari 3
Borås 3
Brescia 3
Buenos Aires 3
Castellarano 3
Coimbatore 3
Cuneo 3
Falls Church 3
Hangzhou 3
Kraków 3
Lanzhou 3
Luxembourg 3
Mumbai 3
Naples 3
Totale 3.545
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 203
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 123
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 119
Characterization of gefitinib uptake in NSCLC cell lines 104
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 104
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 103
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 101
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 98
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 94
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 94
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 91
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 90
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 90
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 89
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 89
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 87
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 86
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 86
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 85
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 84
Physico-chemical characterization and biological evaluation of two fibroin materials 84
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 84
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 84
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 83
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 83
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 82
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 81
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 81
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 79
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 79
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 75
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 75
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 75
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 75
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 73
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 71
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 71
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 70
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 70
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 69
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 67
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 66
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 66
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 64
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 63
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 62
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 62
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 61
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 61
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 61
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 60
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 60
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 59
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 59
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 56
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 55
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 55
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 54
Synergistic activity of letrozole and sorafenib on breast cancer cells 54
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 54
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 54
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 53
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 53
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 53
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 51
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 50
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 50
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 49
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 49
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 48
Immunotherapeutic approaches in malignant pleural mesothelioma 47
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 44
New therapeutic strategies for malignant pleural mesothelioma 43
Targeting FGFR1 pathway in squamous cell lung cancer 42
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 42
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 41
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 41
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 31
null 31
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 13
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 10
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 8
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 5
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 3
Totale 5.674
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.897
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.897
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020717 0 0 45 21 67 127 159 42 94 68 38 56
2020/2021552 13 49 38 37 59 16 48 30 86 23 113 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.723 147 183 121 118 159 196 14 142 540 9 73 21
2023/2024812 38 51 29 43 55 157 68 72 33 45 89 132
2024/2025313 87 112 114 0 0 0 0 0 0 0 0 0
Totale 5.674